SANOFI-ADR (SNY)
US80105N1054 - ADR
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Sanofi reports positive Phase 3 data on Dupixent for COPD (NASDAQ:SNY)
Sanofi's Phase 3 trial of Dupixent for COPD shows significant reduction in exacerbations, potentially making it the first approved biologic for the...
Is NASDAQ:SNY a Good Fit for Dividend Investing?
Is SANOFI-ADR (NASDAQ:SNY) a Good Fit for Dividend Investing?
Sanofi stock ticks higher amid report about spinoff of consumer health business
Sanofi's ADR's rose 0.5% as reports suggest the company is considering separating its consumer health business, working with Rothschild & Co.
Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
This Stock Just Dropped By 15%: Is It a Buy?
Now could be a great opportunity to buy low.
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
/PRNewswire/ -- Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's...
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
/PRNewswire/ -- GLP-1 agonists have become incredibly popular obesity drugs, reshaping the standard of care as people increasingly turn to the new class of...
Sanofi (SNY) Q3 2023 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2023.
Sanofi shares hit 52-week low amid downwardly revised forecast (SNY)
Sanofi (SNY) shares hit a new 52-week low amid a downwardly revised forecast and news that it intends to spin out its consumer products division. Read more here.
Stock Market Correction Intensifies; Google, Meta, Microsoft, Amazon Are Big Earnings Movers: Weekly Review
Microsoft, Google, Amazon and Meta led big earnings.
Why Are Stocks Up Today?
Stocks are up on Friday as investors react to a positive earnings report from Amazon that has other tech stocks moving in sympathy with AMZN.
Why Is Nikola (NKLA) Stock Up 4% Today?
Nikola stock is on the rise Friday as shares of NKLA continue a climb this week on positive news of $165 million award from a court case.
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.
Sanofi Crashes 16% As Third Quarter Comes In Light Ahead Of Spinoff
The company announced plans to spin off its consumer health division.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off the final trading day this week with a breakdown of the biggest pre-market stock movers on Friday!